aetherAI vs Vesta

aetherAI's homepage lists a slide management and viewing system, system planning and implementation, and a scanning solution built with Techman Robot and Hamamatsu Photonics. Valar's Vesta page describes a test that a urologist orders and that Valar says its CLIA-certified laboratory performs. A pathology department and a urology practice are unrelated accounts for these two vendors.

Pathology departments building a scanner-to-viewer rollout are aetherAI's market. The FDA cleared aetherSlide as K233126 for primary diagnosis of scanned FFPE slides, and the company lists ISO 13485 and ISO 27001 certificates.

Urologists treating non-muscle-invasive bladder cancer order Vesta for a BCG response estimate from routine H&E slides, and Valar says the report comes about three days after the sample reaches its lab. Valar says patients with its biomarker face twice the risk of non-response. The BCG papers in J Urol and Eur Urol Oncol, both from 2025, carry Valar affiliations. Valar raised a $22M Series A in May 2024.